Supriya Lifescience (SUPRIYA) Stock Overview
Engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
SUPRIYA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Supriya Lifescience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹842.40 |
| 52 Week High | ₹1,085.00 |
| 52 Week Low | ₹545.50 |
| Beta | 0.63 |
| 1 Month Change | -11.13% |
| 3 Month Change | 32.26% |
| 1 Year Change | 19.59% |
| 3 Year Change | 249.47% |
| 5 Year Change | n/a |
| Change since IPO | 115.53% |
Recent News & Updates
Narrative Update • Jun 16
SUPRIYA: USFDA VAI Outcome And Exports Will Shape Balanced Stock Outlook
Analysts have maintained their price target for Supriya Lifescience at ₹940, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Supriya Lifescience Supriya Lifescience has scheduled a board meeting on May 27, 2026, to consider and approve audited financial results for the quarter and financial year ended March 31, 2026, and to consider a dividend on equity shares for the same period.Narrative Update • Jun 02
SUPRIYA: USFDA VAI Outcome Will Signal Downside Risk To Export Reliance
Analysts have maintained their price target for Supriya Lifescience at ₹940. The steady figure reflects updated assumptions of lower revenue growth, slightly higher profit margins, and a marginally reduced future P/E outlook.Recent updates
Narrative Update • Jun 16
SUPRIYA: USFDA VAI Outcome And Exports Will Shape Balanced Stock Outlook
Analysts have maintained their price target for Supriya Lifescience at ₹940, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Supriya Lifescience Supriya Lifescience has scheduled a board meeting on May 27, 2026, to consider and approve audited financial results for the quarter and financial year ended March 31, 2026, and to consider a dividend on equity shares for the same period.Narrative Update • Jun 02
SUPRIYA: USFDA VAI Outcome Will Signal Downside Risk To Export Reliance
Analysts have maintained their price target for Supriya Lifescience at ₹940. The steady figure reflects updated assumptions of lower revenue growth, slightly higher profit margins, and a marginally reduced future P/E outlook.Analysis Article • May 23
With EPS Growth And More, Supriya Lifescience (NSE:SUPRIYA) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • May 10
SUPRIYA: USFDA VAI Outcome Will Drive April 2026 Board Decisions
Analysts have kept Supriya Lifescience's fair value estimate steady at ₹940, indicating that recent tweaks to assumptions such as the discount rate and future P/E are seen as refinements rather than drivers of a changed price target. What's in the News USFDA issued an Establishment Inspection Report with a Voluntary Action Indicated classification for Supriya Lifescience's API facility at Lote Parshuram, Maharashtra, closing the February 2 to February 6, 2026 inspection cycle and confirming ongoing cGMP compliance (Regulatory filing).Narrative Update • Apr 26
SUPRIYA: Bullish View Will Center On April 2026 Board And Director Decisions
Analysts have kept their price target for Supriya Lifescience steady at ₹940, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A special or extraordinary shareholders meeting is scheduled for April 10, 2026 via postal ballot in India to consider appointing Mr. Manish Panchal as a non executive independent director for a five year term from February 9, 2026 to February 8, 2031 (Key Developments).Narrative Update • Apr 08
SUPRIYA: Bullish View Will Focus On April 2026 Shareholder Decisions
Analysts have kept Supriya Lifescience's fair value estimate steady at ₹940. This reflects unchanged views on its discount rate, revenue growth outlook, profit margin expectations and future P/E assumptions.Narrative Update • Mar 25
SUPRIYA: Bullish View Will Await April 2026 Shareholder Meeting Outcome
Analysts are maintaining their fair value estimate for Supriya Lifescience at ₹940 per share. This reflects unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, which together support a steady view on the company’s valuation outlook.Narrative Update • Mar 11
SUPRIYA: Bullish View Will Await February 2026 Results As Key Catalyst
Analysts have kept their price target for Supriya Lifescience steady at ₹940, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The board has scheduled a meeting for Feb 09, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative Update • Feb 24
SUPRIYA: Steady Thesis Will Rely On Upcoming February 2026 Results Catalyst
Analysts have kept their fair value estimate for Supriya Lifescience steady at ₹940. They explain the unchanged price target by relatively similar assumptions on revenue growth, profit margins and future P/E compared with their prior model.Narrative Update • Feb 10
SUPRIYA: Future Returns Will Reflect Steady Thesis And Upcoming Results Catalyst
Analysts have kept their fair value estimate for Supriya Lifescience steady at ₹940.0, with the latest tweak in assumptions mainly reflecting a slightly adjusted discount rate and future P/E expectations rather than a change in the underlying thesis. What's in the News A board meeting is scheduled for February 9, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analysis Article • Jan 29
Supriya Lifescience Limited's (NSE:SUPRIYA) Business Is Yet to Catch Up With Its Share Price
With a price-to-earnings (or "P/E") ratio of 29.2x Supriya Lifescience Limited ( NSE:SUPRIYA ) may be sending bearish...Narrative Update • Jan 26
SUPRIYA: Future Returns Will Reflect Higher P E Expectations And Earnings Visibility
Analysts have lifted their fair value estimate for Supriya Lifescience from ₹850 to ₹940, citing updated assumptions around future P/E levels while keeping growth, margins and the discount rate broadly unchanged. What's in the News Board meeting scheduled for Nov 12, 2025, at 15:00 Indian Standard Time to consider and approve unaudited financial results for the quarter and half year ended Sep 30, 2025, along with the statutory auditors' limited review report (company filing).Narrative Update • Jan 10
SUPRIYA: Future Returns Will Reflect Stable Board Oversight And Dividend Confidence
Analysts have maintained their fair value estimate for Supriya Lifescience at ₹850.0. This reflects unchanged views on discount rate, revenue growth, profit margin and future P/E assumptions that continue to support this target. What's in the News Board meeting scheduled for November 12, 2025, at 15:00 Indian Standard Time, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).Narrative Update • Dec 17
SUPRIYA: Future Returns Will Reflect WHO GMP Certification And Dividend Confidence
Analysts have maintained their price target for Supriya Lifescience at ₹850.00 per share, citing stable assumptions on the discount rate, revenue growth, profit margins, and future valuation multiples as justification for keeping their outlook unchanged. What's in the News World Health Organisation grants WHO GMP certification for inhalation dosages at Supriya Lifescience's Ambernath facility, enabling production, sale, and wider global distribution from the site (Regulatory filing).Narrative Update • Dec 03
SUPRIYA: Future Returns Will Reflect WHO GMP Certification-Driven Expansion
Analysts have modestly reiterated their conviction in Supriya Lifescience with an unchanged fair value estimate of ₹850.00 per share, reflecting stable assumptions on growth, profitability, and valuation multiples. What's in the News The World Health Organization has granted WHO GMP certification for Supriya Lifescience’s Ambernath facility for inhalation dosages, enabling production, sale, and wider global distribution from the site (Regulatory filing).Narrative Update • Nov 19
SUPRIYA: Future Performance To Reflect Improved Margins And WHO-GMP Certification
Analysts have raised their price target for Supriya Lifescience from ₹800 to ₹850, citing stronger revenue growth projections and improved profit margins. What's in the News The board meeting is scheduled for November 12, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025.Narrative Update • Aug 23
Expansion Into Regulated Markets And CMO/CDMO Opportunities To Strengthen Future Prospects
Despite a substantial increase in consensus revenue growth forecasts and a notable reduction in future P/E, analysts have revised Supriya Lifescience’s fair value down from ₹843 to ₹800. What's in the News Board meeting scheduled to approve unaudited financial results for the quarter ended June 30, 2025.Analysis Article • Jul 03
Supriya Lifescience Limited's (NSE:SUPRIYA) Shareholders Might Be Looking For Exit
It's not a stretch to say that Supriya Lifescience Limited's ( NSE:SUPRIYA ) price-to-earnings (or "P/E") ratio of...Analysis Article • Apr 04
Here's Why We Think Supriya Lifescience (NSE:SUPRIYA) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Mar 04
Subdued Growth No Barrier To Supriya Lifescience Limited's (NSE:SUPRIYA) Price
It's not a stretch to say that Supriya Lifescience Limited's ( NSE:SUPRIYA ) price-to-earnings (or "P/E") ratio of...
New Narrative • Feb 11
Expansion Into High-Margin Therapeutic Segments Like Anti-Stimulants Will Strengthen Future Prospects
Expanding into high-margin therapeutic segments and increasing exports highlight Supriya Lifescience's potential for robust future revenue growth.Analysis Article • Nov 07
Supriya Lifescience Limited (NSE:SUPRIYA) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Supriya Lifescience Limited ( NSE:SUPRIYA ) shares have continued their recent momentum with a 26% gain in the last...Analysis Article • Sep 08
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
The board of Supriya Lifescience Limited ( NSE:SUPRIYA ) has announced that it will be paying its dividend of ₹0.80 on...Analysis Article • Jun 05
We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Supriya Lifescience Limited's ( NSE:SUPRIYA ) healthy profit numbers didn't contain any surprises for investors...Analysis Article • May 10
Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
With a price-to-earnings (or "P/E") ratio of 24.6x Supriya Lifescience Limited ( NSE:SUPRIYA ) may be sending bullish...Analysis Article • Feb 09
Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider...Analysis Article • May 28
Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
The recent earnings posted by Supriya Lifescience Limited ( NSE:SUPRIYA ) were solid, but the stock didn't move as much...Analysis Article • May 07
Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
The Supriya Lifescience Limited ( NSE:SUPRIYA ) share price has fared very poorly over the last month, falling by a...Shareholder Returns
| SUPRIYA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -17.3% | 2.3% | 1.8% |
| 1Y | 19.6% | 13.2% | -0.9% |
Return vs Industry: SUPRIYA exceeded the Indian Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: SUPRIYA exceeded the Indian Market which returned -0.9% over the past year.
Price Volatility
| SUPRIYA volatility | |
|---|---|
| SUPRIYA Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SUPRIYA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SUPRIYA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 515 | Saloni Wagh | www.supriyalifescience.com |
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products.
Supriya Lifescience Limited Fundamentals Summary
| SUPRIYA fundamental statistics | |
|---|---|
| Market cap | ₹67.80b |
| Earnings (TTM) | ₹2.09b |
| Revenue (TTM) | ₹8.28b |
32.4x
P/E Ratio8.2x
P/S RatioIs SUPRIYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUPRIYA income statement (TTM) | |
|---|---|
| Revenue | ₹8.28b |
| Cost of Revenue | ₹2.54b |
| Gross Profit | ₹5.74b |
| Other Expenses | ₹3.65b |
| Earnings | ₹2.09b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.98 |
| Gross Margin | 69.32% |
| Net Profit Margin | 25.26% |
| Debt/Equity Ratio | 0% |
How did SUPRIYA perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 17:01 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Supriya Lifescience Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maitri Sheth | Choice Equity Broking Private Limited |
| null null | K.R. Choksey Shares & Securities Private Ltd. |